|
Volume 2, Number 2 February, 2003 |
||
|
The following articles appeared in this month's issues of the surveyed journals. Articles that seem to be of most interest to the practicing gynecologic oncologist are included. The journals that are surveyed are New England Journal of Medicine, Journal of Clinical Oncology, Gynecologic Oncology, Cancer, American Journal of Obstetrics and Gynecology, Lancet, Cancer Research, Obstetrics and Gynecology, Journal of the National Cancer Institute, Journal of the American Medical Association. The participants in this program are the active clinical fellows at Memorial Hospital: Bhavana Pothuri, Mario Leitao, Christopher Awtrey, Sarah Ferguson, Alan Schlaerth and Rami Eitan. The managing editor is Douglas Levine. Comments, questions, complaints and suggestions are always welcome, please E-mail us at: VJC@smgo.org or click here. To subscribe or unsubscribe to the VJC, click here. Gynecologic Oncology Mario Leitao In the February issue of Gynecologic Oncology there were a limited number of articles due to the publication of the SGO 2003 abstracts, which can be found below. Title: Abstracts Presented for the Thirty-Fourth Annual Meeting of the Society of Gynecologic Oncologists Authors: The SGO members and guests. Source: Gynecologic Oncology, Volume 88, Issue 2, February 2003, Pages 156-261. Journal of Clinical Oncology - Bhavana Pothuri There were no original research articles this month in JCO, however, there was a very nice review of hereditary breast and ovarian cancer syndrome, which covered many aspects related to pathogenesis, management, and societal issues. Title: Hereditary Breast-Ovarian Cancer at the Bedside: Role of the Medical Oncologist Authors: Lynch, Henry T., Snyder, Carrie L., Lynch, Jane F., Riley, Bronson D., Rubinstein, Wendy S. Source: J Clin Oncol 2003 21: 740-753 Click here for abstract from JCO Journal of the National Cancer Institute Rami Eitan Since gynecologic oncologists are often counseling patients regarding risks associated with BRCA1/2 mutations, the following article has been included. Title: BRCA2 Germline Mutations in Familial Pancreatic Carcinoma Authors: Stephan A. Hahn, Bill Greenhalf, Ian Ellis, Mercedes Sina-Frey, Harald Rieder, Birgit Korte, Berthold Gerdes, Ralf Kress, Andreas Ziegler, John A. Raeburn, Donata Campra, Robert Grόtzmann, Helga Rehder, Matthias Rothmund, Wolff Schmiegel, John P. Neoptolemos, and Detlef K. Bartsch Source: J Natl Cancer Inst 2003; 95: 214-221. Summary: To study the frequency of BRCA2 mutations in hereditary pancreatic cancer 26 European families in which at least two first-degree relatives had a histologically confirmed diagnosis of pancreatic ductal adenocarcinoma were identified. Genomic DNA from peripheral blood was sequenced. Three (12%) families carried germline frameshift mutations in that are predicted to result in a truncated BRCA2 protein. Two (7%) additional families harbored mutations designated as unclassified variants of BRCA2. None of the families in met criteria for hereditary breast or ovarian cancer. The data suggest a role for BRCA2 germline mutations in a subpopulation of familial pancreatic cancer.
Click here for abstract from JNCI Obstetrics and Gynecology Alan Schlaerth Title: Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary Authors: Jacob Tangir, Daniel Zelterman, Wenging Ma and Peter E. Schwartz Source: Obstetrics & Gynecology, Volume 101, Issue 2, February 2003, Pages 251-257. Summary: This retrospective case series analyzed the long-term effects of fertility sparing treatment for malignant germ cell tumors of the ovary in 64 patients, of which 38 attempted to conceive. 29 (76%) conceived after surgical treatment with or without chemotherapy: 16 had VAC, 9 had platinum-based chemo, 4 had no chemo. In 16 available offspring, there were no congenital abnormalities. Fertility sparing surgery followed by chemotherapy appears to conserve the reproductive function of women with malignant germ cell tumors. Click here for abstract from Obstetrics & Gynecology American Journal of Obstetrics and Gynecology Chris Awtrey Title: Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer Authors: B. Gull MD, PhD, B. Karlsson MD, PhD, I. Milsom MD, PhD and S. Granberg MD, PhD Source: Am J Obstet Gynecol 2003;188:401-8. Summary: 394 women with postmenopausal bleeding were enrolled to evaluate the use of TV ultrasound in evaluating endometrial thickness and predicting presence or development of endometrial cancer or atypia. All patients were followed for ≥ 10 years. 5.8% of women referred for PMB developed endometrial cancer. No patients with an endometrial thickness of ≤ 4mm developed EMCA or atypia even if they had recurrent bleeding episodes. Patients with an endometrium > 4mm had a increased relative risk for EMCA, RR = 44.5. The authors conclude that TVUS is an excellent tool for determining whether further investigation is necessary. Click here for abstract from Am J Ob Gyn New England Journal of Medicine Bhavana Pothuri Title: Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer Authors: Munoz, Nubia, Bosch, F. Xavier, de Sanjose, Silvia, Herrero, Rolando, Castellsague, Xavier, Shah, Keerti V., Snijders, Peter J.F., Meijer, Chris J.L.M., the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group Source: N Engl J Med 2003 348: 518-527 Summary: The purpose of this study was to assess the risk associated with various HPV types. The authors pooled data from 11 case control studies from 9 countries- 1918 women with histologically confirmed SCCA and 1928 control women. Personal interviews were conducted and cervical cells were collected for HPV DNA typing. Based on the primers used, HPV DNA was noted in 90.7 % and 96.6 % of patients with cervical cancer, and 13.4 or 15.6 % of controls. The most common HPV types in descending frequency in cx ca patients were: 16, 18, 45, 31, 33, 52, 58, and 35. Among, the controls the most common types were: 16, 18, 45, 31, 6, 58, 35, and 33. Fifteen HPV types were classified as high-risk types; 3 were classified as probable high-risk types; and 12 were classified as low-risk types. The authors conclude that in addition to HPV types 16 and 18, types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 should be considered carcinogenic, or high-risk types, and types 26, 53, and 66 should be considered probably carcinogenic. Click here for abstract from N Engl J Med Journal of the American Medical Association Rami Eitan Nothing of interest this month Cancer Sarah Ferguson Nothing of interest this month Lancet Chris Awtrey Nothing of interest this month Cancer Research Sarah Ferguson Title: The Human Lipid Phosphate Phosphatase-3 Decreases the Growth, Survival, and Tumorigenesis of Ovarian Cancer Cells: Validation of the Lysophosphatidic Acid Signaling Cascade as a Target for Therapy in Ovarian Cancer Authors: Tanyi, Janos L., Morris, Andrew J., Wolf, Judith K., Fang, Xianjun, Hasegawa, Yutaka, Lapushin, Ruth, Auersperg, Nelly, Sigal, Yury J., Newman, Robert A., Felix, Edward A., Atkinson, Edward N., Mills, Gordon B. Source: Cancer Res 2003 63: 1073-1082 Summary: Lysophosphatidic acid (LPA) is elevated in ascites and plasma of women with ovarian cancer. LPA can induce ovarian cells to proliferate and increase their metastatic potential. Human lipid phosphate phosphohydrolas-3 (hLPP-3), which hydrolyzes LPA, was introduced into ovarian cancer cell lines and decreased the colony-forming activity, increased apoptosis and decreased tumor growth. Pharmacologic manipulation of LPA metabolism may be a potential target for therapy for ovarian cancer. |
Copyright ©2003, SMGO, All Rights Reserved.